Loading…
Reported covered position: Director of Legislative Affairs
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Pharmaceutical Information Exchange Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Pharmaceutical Information Exchange Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2018 · third_quarter · 3A
Met with HHS officials regarding the Administration Blueprint to Lower Drug Prices. Submitted comments to HHS in response to Blueprint. Communications and correspondence related to suspension of claims under Medicare Part D for a credible allegation of fraud, electronic prescribing, and prior authorization under Medicare Part D contained in HR 6--The Opioid Crisis Response Act of 2018.
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Source: Senate LDA
Pharmaceutical Information Exchange Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Joined other stakeholders in a letter to Reps. Mullin and Blumenauer of support for H.R. 3545 - Overdose Prevention and Patient Safety Act, also sent a letter of support of H.R. 3545 to House Energy and Commerce Committee in support of H.R.3545 , Joined other stakeholders in letter to Senate and House leadership in support of the CREATES Act (H.R.2212 and S. 974) Delivered remarks at FDA Opioid Policy Steering Committee on ways to address the opioid epidemic, dissemination of pharmacoeconomic information,submitted letter to House Energy and Commerce Committee in support of H.R. 2026 Pharmaceutical Information Exchange Act and submitted a letter to AHRQ in response to a request for information regarding patient reported outcomes measures.
Pharmaceutical Information Exchange Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Pharmaceutical Information Exchange Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Submitted a letter to House Energy and Commerce Committee Chair and Ranking Member in support of H.R. 3545 - Overdose Prevention and Patient Safety Act. Also sent a letter for the House Energy and Commerce Committee record in support of H.R. 4275 which directs the Secretary of HHS to develop and disseminate materials, giving pharmacists the understanding and ability to decline to fill controlled substances prescriptions that are fraudulent, forged or appear to be for abuse or diversion. Sent a letter in support of S. 974, the CREATES Act to the Chairman and Ranking Member of the Senate Judiciary Committee. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
CREATES Act of 2017
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Joined other stakeholders in a letter to Reps. Mullin and Blumenauer of support for H.R. 3545 - Overdose Prevention and Patient Safety Act, also sent a letter of support of H.R. 3545 to House Energy and Commerce Committee in support of H.R.3545 , Joined other stakeholders in letter to Senate and House leadership in support of the CREATES Act (H.R.2212 and S. 974) Delivered remarks at FDA Opioid Policy Steering Committee on ways to address the opioid epidemic, dissemination of pharmacoeconomic information,submitted letter to House Energy and Commerce Committee in support of H.R. 2026 Pharmaceutical Information Exchange Act and submitted a letter to AHRQ in response to a request for information regarding patient reported outcomes measures.
Every Prescription Conveyed Securely Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Submitted letter to the House Energy and Commerce Committee for the record in support of H.R. 4841 concerning standardizing electronic prior authorization for Medicare. Also sent a letter to Rep. Schweikert in support of H.R. 4841. Also sent a letter of support for H.R. 3528 for the House Energy and Commerce Committee record. H.R. 3528 provides for the e-prescribing of prescription drugs for controlled substances under Medicare Part D program. Participated in discussions on the need to address fraud, waste and abuse in the Medicare Part D program.
Every Prescription Conveyed Securely Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Submitted letter to the House Energy and Commerce Committee for the record in support of H.R. 4841 concerning standardizing electronic prior authorization for Medicare. Also sent a letter to Rep. Schweikert in support of H.R. 4841. Also sent a letter of support for H.R. 3528 for the House Energy and Commerce Committee record. H.R. 3528 provides for the e-prescribing of prescription drugs for controlled substances under Medicare Part D program.
Overdose Prevention and Patient Safety Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Submitted a letter to House Energy and Commerce Committee Chair and Ranking Member in support of H.R. 3545 - Overdose Prevention and Patient Safety Act. Also sent a letter for the House Energy and Commerce Committee record in support of H.R. 4275 which directs the Secretary of HHS to develop and disseminate materials, giving pharmacists the understanding and ability to decline to fill controlled substances prescriptions that are fraudulent, forged or appear to be for abuse or diversion. Sent a letter in support of S. 974, the CREATES Act to the Chairman and Ranking Member of the Senate Judiciary Committee. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Overdose Prevention and Patient Safety Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Submitted a letter to House Energy and Commerce Committee Chair and Ranking Member in support of H.R. 3545 - Overdose Prevention and Patient Safety Act. Also sent a letter for the House Energy and Commerce Committee record in support of H.R. 4275 which directs the Secretary of HHS to develop and disseminate materials, giving pharmacists the understanding and ability to decline to fill controlled substances prescriptions that are fraudulent, forged or appear to be for abuse or diversion. Sent a letter in support of S. 974, the CREATES Act to the Chairman and Ranking Member of the Senate Judiciary Committee.
Overdose Prevention and Patient Safety Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Joined other stakeholders in a letter to Reps. Mullin and Blumenauer of support for H.R. 3545 - Overdose Prevention and Patient Safety Act, also sent a letter of support of H.R. 3545 to House Energy and Commerce Committee in support of H.R.3545 , Joined other stakeholders in letter to Senate and House leadership in support of the CREATES Act (H.R.2212 and S. 974) Delivered remarks at FDA Opioid Policy Steering Committee on ways to address the opioid epidemic, dissemination of pharmacoeconomic information,submitted letter to House Energy and Commerce Committee in support of H.R. 2026 Pharmaceutical Information Exchange Act and submitted a letter to AHRQ in response to a request for information regarding patient reported outcomes measures.
Small Business Disaster Relief Act of 2017
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Submitted comments to CMS on Medicare Advantage and Medicare Part D Rule, joined other stakeholders in letter HHS OIG in support of a safe harbor provision for that would encourage development of value-based contracts for the Medicare and Medicaid populations,submitted comments to CMS on the 2019 draft Call letter and submitted letter to Rep. Schweikert in support of H.R. 4148 concerning standardizing electronic prior authorization for Medicare beneficiaries.
Empowering Pharmacists in the Fight Against Opioid Abuse Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Submitted a letter to House Energy and Commerce Committee Chair and Ranking Member in support of H.R. 3545 - Overdose Prevention and Patient Safety Act. Also sent a letter for the House Energy and Commerce Committee record in support of H.R. 4275 which directs the Secretary of HHS to develop and disseminate materials, giving pharmacists the understanding and ability to decline to fill controlled substances prescriptions that are fraudulent, forged or appear to be for abuse or diversion. Sent a letter in support of S. 974, the CREATES Act to the Chairman and Ranking Member of the Senate Judiciary Committee.
Empowering Pharmacists in the Fight Against Opioid Abuse Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Submitted a letter to House Energy and Commerce Committee Chair and Ranking Member in support of H.R. 3545 - Overdose Prevention and Patient Safety Act. Also sent a letter for the House Energy and Commerce Committee record in support of H.R. 4275 which directs the Secretary of HHS to develop and disseminate materials, giving pharmacists the understanding and ability to decline to fill controlled substances prescriptions that are fraudulent, forged or appear to be for abuse or diversion. Sent a letter in support of S. 974, the CREATES Act to the Chairman and Ranking Member of the Senate Judiciary Committee. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Submitted letter to the House Energy and Commerce Committee for the record in support of H.R. 4841 concerning standardizing electronic prior authorization for Medicare. Also sent a letter to Rep. Schweikert in support of H.R. 4841. Also sent a letter of support for H.R. 3528 for the House Energy and Commerce Committee record. H.R. 3528 provides for the e-prescribing of prescription drugs for controlled substances under Medicare Part D program.
Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Submitted letter to the House Energy and Commerce Committee for the record in support of H.R. 4841 concerning standardizing electronic prior authorization for Medicare. Also sent a letter to Rep. Schweikert in support of H.R. 4841. Also sent a letter of support for H.R. 3528 for the House Energy and Commerce Committee record. H.R. 3528 provides for the e-prescribing of prescription drugs for controlled substances under Medicare Part D program. Participated in discussions on the need to address fraud, waste and abuse in the Medicare Part D program.
SUPPORT for Patients and Communities Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Met with HHS officials regarding the Administration Blueprint to Lower Drug Prices. Submitted comments to HHS in response to Blueprint. Communications and correspondence related to suspension of claims under Medicare Part D for a credible allegation of fraud, electronic prescribing, and prior authorization under Medicare Part D contained in HR 6--The Opioid Crisis Response Act of 2018.
SUPPORT for Patients and Communities Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Met with HHS officials regarding the Administration Blueprint to Lower Drug Prices. Submitted comments to HHS in response to Blueprint. Communications and correspondence related to suspension of claims under Medicare Part D for a credible allegation of fraud, electronic prescribing, and prior authorization under Medicare Part D contained in HR 6--The Opioid Crisis Response Act of 2018.
SUPPORT for Patients and Communities Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Met with HHS officials regarding the Administration Blueprint to Lower Drug Prices. Submitted comments to HHS in response to Blueprint. Communications and correspondence related to suspension of claims under Medicare Part D for a credible allegation of fraud, electronic prescribing, and prior authorization under Medicare Part D contained in HR 6--The Opioid Crisis Response Act of 2018.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Joined other stakeholders in a letter to Reps. Mullin and Blumenauer of support for H.R. 3545 - Overdose Prevention and Patient Safety Act, also sent a letter of support of H.R. 3545 to House Energy and Commerce Committee in support of H.R.3545 , Joined other stakeholders in letter to Senate and House leadership in support of the CREATES Act (H.R.2212 and S. 974) Delivered remarks at FDA Opioid Policy Steering Committee on ways to address the opioid epidemic, dissemination of pharmacoeconomic information,submitted letter to House Energy and Commerce Committee in support of H.R. 2026 Pharmaceutical Information Exchange Act and submitted a letter to AHRQ in response to a request for information regarding patient reported outcomes measures.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Submitted a letter to House Energy and Commerce Committee Chair and Ranking Member in support of H.R. 3545 - Overdose Prevention and Patient Safety Act. Also sent a letter for the House Energy and Commerce Committee record in support of H.R. 4275 which directs the Secretary of HHS to develop and disseminate materials, giving pharmacists the understanding and ability to decline to fill controlled substances prescriptions that are fraudulent, forged or appear to be for abuse or diversion. Sent a letter in support of S. 974, the CREATES Act to the Chairman and Ranking Member of the Senate Judiciary Committee.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Submitted a letter to House Energy and Commerce Committee Chair and Ranking Member in support of H.R. 3545 - Overdose Prevention and Patient Safety Act. Also sent a letter for the House Energy and Commerce Committee record in support of H.R. 4275 which directs the Secretary of HHS to develop and disseminate materials, giving pharmacists the understanding and ability to decline to fill controlled substances prescriptions that are fraudulent, forged or appear to be for abuse or diversion. Sent a letter in support of S. 974, the CREATES Act to the Chairman and Ranking Member of the Senate Judiciary Committee. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Pharmaceutical Information Exchange Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Joint letter with other pharmacy associations submitted for the record in the House Energy and Commerce committee hearing on opioids in support of pharmacists being eligible for DATA waivers to provide Medication Assisted Therapy, Comments submitted to HHS Notice of Benefit and payment parameters for 2019;Comments submitted to FDA on direct to consumer advertising, Comments submitted to FDA on potential areas of focus for the opioid policy steering committee, comments submitted to the FTC on solutions and strategies to improve generic competition in the marketplace, comments submitted in response to a request for information from the House of Representatives Diabetes Caucus for information on value based contracting, dissemination of pharmaeconomic information, and H.R. 2026 Pharmaceutical Information Exchange Act.
Pharmaceutical Information Exchange Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Letters of support for the CREATES Act (H.R. 2212 and S. 974), (H.R. 3545) The Overdose Prevention and Patient Safety Act and the Pharmaceutical Information Exchange Act(H.R. 2026). Comments to FDA on Hatch-Waxman reform to advocate for prohibition of strategies that unnecessarily delay the entry of generic drugs into the marketplace.
Pharmaceutical Information Exchange Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Letters of support for the CREATES Act (H.R. 2212 and S. 974), the FAST Act (H.R. 2051) and the Pharmaceutical Information Exchange Act(H.R. 2026). Comments to FDA on biosimilars and interchangeability,
FAST Generics Act of 2017
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Letters of support for the CREATES Act (H.R. 2212 and S. 974), the FAST Act (H.R. 2051) and the Pharmaceutical Information Exchange Act(H.R. 2026). Comments to FDA on biosimilars and interchangeability,
CREATES Act of 2017
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Letters of support for the CREATES Act (H.R. 2212 and S. 974), (H.R. 3545) The Overdose Prevention and Patient Safety Act and the Pharmaceutical Information Exchange Act(H.R. 2026). Comments to FDA on Hatch-Waxman reform to advocate for prohibition of strategies that unnecessarily delay the entry of generic drugs into the marketplace.
CREATES Act of 2017
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Letters of support for the CREATES Act (H.R. 2212 and S. 974), the FAST Act (H.R. 2051) and the Pharmaceutical Information Exchange Act(H.R. 2026). Comments to FDA on biosimilars and interchangeability,
Overdose Prevention and Patient Safety Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Letters of support for the CREATES Act (H.R. 2212 and S. 974), (H.R. 3545) The Overdose Prevention and Patient Safety Act and the Pharmaceutical Information Exchange Act(H.R. 2026). Comments to FDA on Hatch-Waxman reform to advocate for prohibition of strategies that unnecessarily delay the entry of generic drugs into the marketplace.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Letters of support for the CREATES Act (H.R. 2212 and S. 974), (H.R. 3545) The Overdose Prevention and Patient Safety Act and the Pharmaceutical Information Exchange Act(H.R. 2026). Comments to FDA on Hatch-Waxman reform to advocate for prohibition of strategies that unnecessarily delay the entry of generic drugs into the marketplace.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Letters of support for the CREATES Act (H.R. 2212 and S. 974), the FAST Act (H.R. 2051) and the Pharmaceutical Information Exchange Act(H.R. 2026). Comments to FDA on biosimilars and interchangeability,
FAST Generics Act of 2015
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, providing comments to the FDA on the impact of Risk Evaluation Mitigation Strategies (REMS), supporting H.R. 2841 designed to increase access to generic drugs and providing comments to CMS on benefit and payment parameters for 2017. Support S. 524 (CARA). Comments provided to SAMSHA and AHRQ on opioid abuse. Comments provided on S. 2700 concerning an exemption for biological medicines from USP standards for quality. Comments provided to CMS on MACRA proposed rule.
FAST Generics Act of 2015
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, providing comments to the FDA on the impact of Risk Evaluation Mitigation Strategies (REMS), supporting H.R. 2841 designed to increase access to generic drugs and providing comments to CMS on benefit and payment parameters for 2017.
FAST Generics Act of 2015
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, providing comments to the FDA on the impact of Risk Evaluation Mitigation Strategies (REMS), supporting H.R. 2841 designed to increase access to generic drugs and providing comments to CMS on benefit and payment parameters for 2017. Support S. 524 (CARA). Comments provided to SAMSHA and AHRQ on opioid abuse. Comments provided on S. 2700 concerning an exemption for biological medicines from USP standards for quality. Comments provided to CMS on MACRA proposed rule. Comments to FDA on biosimilars labeling draft guidance advocating for changes to the biosimilarity statement and biosimilar product identification and naming sections. Comments to the FDA on PDUFA VI reauthorization. for its continued focus on patient safety and quality patient care. Meetings with Congressional office staff to seek support for amending current law consistent with HIPAA to allow health plans to access patient addiction records.
21st Century Cures Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries (S. 1913),Biosimilar naming, Medicare Part D, AMCP draft legislation - "Medicare Prescription Drug Anti-Fraud Act", Medicare Part B reimbursement of biosimilars, Medicare Part B Drug Demonstration Projects, Senate Innovations Initiative and Medication Therapy Management (MTM)
21st Century Cures Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries (S. 1913),Biosimilar naming, Medicare Part D, AMCP draft legislation - "Medicare Prescription Drug Anti-Fraud Act", Medicare Part B reimbursement of biosimilars, Medicare Part B Drug Demonstration Projects, Senate Innovations Initiative and Medication Therapy Management (MTM)
21st Century Cures Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries (S. 1913),Biosimilar naming, Medicare Part D, AMCP draft legislation - "Medicare Prescription Drug Anti-Fraud Act", Medicare Part B reimbursement of biosimilars, Senate Innovations Initiative and Medication Therapy Management (MTM)
Stopping Medication Abuse and Protecting Seniors Act of 2015
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries (S. 1913),Biosimilar naming, Medicare Part D, AMCP draft legislation - "Medicare Prescription Drug Anti-Fraud Act", Medicare Part B reimbursement of biosimilars, Medicare Part B Drug Demonstration Projects, Senate Innovations Initiative and Medication Therapy Management (MTM)
Stopping Medication Abuse and Protecting Seniors Act of 2015
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries (S. 1913),Biosimilar naming, Medicare Part D, AMCP draft legislation - "Medicare Prescription Drug Anti-Fraud Act", Medicare Part B reimbursement of biosimilars, Medicare Part B Drug Demonstration Projects, Senate Innovations Initiative and Medication Therapy Management (MTM)
Stopping Medication Abuse and Protecting Seniors Act of 2015
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries (S. 1913),Biosimilar naming, Medicare Part D, AMCP draft legislation - "Medicare Prescription Drug Anti-Fraud Act", Medicare Part B reimbursement of biosimilars, Senate Innovations Initiative and Medication Therapy Management (MTM)
FDA and NIH Workforce Authorities Modernization Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, providing comments to the FDA on the impact of Risk Evaluation Mitigation Strategies (REMS), supporting H.R. 2841 designed to increase access to generic drugs and providing comments to CMS on benefit and payment parameters for 2017. Support S. 524 (CARA). Comments provided to SAMSHA and AHRQ on opioid abuse. Comments provided on S. 2700 concerning an exemption for biological medicines from USP standards for quality. Comments provided to CMS on MACRA proposed rule. Comments to FDA on biosimilars labeling draft guidance advocating for changes to the biosimilarity statement and biosimilar product identification and naming sections. Comments to the FDA on PDUFA VI reauthorization. for its continued focus on patient safety and quality patient care. Meetings with Congressional office staff to seek support for amending current law consistent with HIPAA to allow health plans to access patient addiction records.
FDA and NIH Workforce Authorities Modernization Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, providing comments to the FDA on the impact of Risk Evaluation Mitigation Strategies (REMS), supporting H.R. 2841 designed to increase access to generic drugs and providing comments to CMS on benefit and payment parameters for 2017. Support S. 524 (CARA). Comments provided to SAMSHA and AHRQ on opioid abuse. Comments provided on S. 2700 concerning an exemption for biological medicines from USP standards for quality. Comments provided to CMS on MACRA proposed rule.
Comprehensive Addiction and Recovery Act of 2016
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, providing comments to the FDA on the impact of Risk Evaluation Mitigation Strategies (REMS), supporting H.R. 2841 designed to increase access to generic drugs and providing comments to CMS on benefit and payment parameters for 2017. Support S. 524 (CARA). Comments provided to SAMSHA and AHRQ on opioid abuse. Comments provided on S. 2700 concerning an exemption for biological medicines from USP standards for quality. Comments provided to CMS on MACRA proposed rule. Comments to FDA on biosimilars labeling draft guidance advocating for changes to the biosimilarity statement and biosimilar product identification and naming sections. Comments to the FDA on PDUFA VI reauthorization. for its continued focus on patient safety and quality patient care. Meetings with Congressional office staff to seek support for amending current law consistent with HIPAA to allow health plans to access patient addiction records.
Comprehensive Addiction and Recovery Act of 2016
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, providing comments to the FDA on the impact of Risk Evaluation Mitigation Strategies (REMS), supporting H.R. 2841 designed to increase access to generic drugs and providing comments to CMS on benefit and payment parameters for 2017. Support S. 524 (CARA). Comments provided to SAMSHA and AHRQ on opioid abuse. Comments provided on S. 2700 concerning an exemption for biological medicines from USP standards for quality. Comments provided to CMS on MACRA proposed rule.
National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, supporting the reauthorization of the National All Schedules Prescription Electronic Reporting Act (S 480/HR 1725)and providing comments to CDC on opioid dispensing guidelines
FAST Generics Act of 2015
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, providing comments to the FDA on the impact of Risk Evaluation Mitigation Strategies (REMS), supporting H.R. 2841 designed to increase access to generic drugs and providing comments to CMS on benefit and payment parameters for 2017.
21st Century Cures Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries (S. 1913),Biosimilar naming, Medicare Part D, AMCP draft legislation - "Medicare Prescription Drug Anti-Fraud Act", Medicare Part B reimbursement of biosimilars, Senate Innovations Initiative
21st Century Cures Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries (S. 1913),Biosimilar naming, Medicare Part D, AMCP draft legislation - "Medicare Prescription Drug Anti-Fraud Act", Medicare Part B reimbursement of biosimilars, Senate Innovations Initiative and Medication Therapy Management (MTM)
21st Century Cures Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries,Biosimilar naming, Medicare Part D
Stopping Medication Abuse and Protecting Seniors Act of 2015
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries (S. 1913),Biosimilar naming, Medicare Part D, AMCP draft legislation - "Medicare Prescription Drug Anti-Fraud Act", Medicare Part B reimbursement of biosimilars, Senate Innovations Initiative and Medication Therapy Management (MTM)
Stopping Medication Abuse and Protecting Seniors Act of 2015
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries (S. 1913),Biosimilar naming, Medicare Part D, AMCP draft legislation - "Medicare Prescription Drug Anti-Fraud Act", Medicare Part B reimbursement of biosimilars, Senate Innovations Initiative
National All Schedules Prescription Electronic Reporting Reauthorization Act of 2016
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, supporting the reauthorization of the National All Schedules Prescription Electronic Reporting Act (S 480/HR 1725)and providing comments to CDC on opioid dispensing guidelines
Medication Therapy Management Empowerment Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S557/HR1024 legislation that would expand Medicare Part D Medication Therapy Management benefit to one or more chronic diseases as defined in the legislation; Controlled substances -- advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled subances in the Medicare Part D program; Preferred networks - advocating that CMS recognize the importance of the useof preferred networks to improve pharmacy performance measures; CMS Proposed Rule/Medicare Part D, including HR 4160
Medication Therapy Management Empowerment Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S557/HR 1024 legislation that would expand Medicare Part D Medication Therapy Management benefit to one or more chronic diseases as defined in the legislation; Controlled substances--advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program.
Medication Therapy Management Empowerment Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S557/HR1024 legislation that would expand Medicare Part D Medication Therapy Management benefit to one or more chronic diseases as defined in the legislation; Controlled substances--advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program.
National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Support for legislation (National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013-NASPER) to reauthorize the controlled substance monitoring programs under the Public Health Service Act designed to foster the establishment of state-administered prescription drug monitoring programs (S 2529/HR 3528)
National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Support for legislation (National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013 - NAPSER) to reauthorize the controlled substance monitoring programs under the Public Health Service Act designed to foster the establishment of state-administered prescription drug monitoring programs (S 2529/HR 3528).
National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Support for legislation (National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013- NASPER) to reauthorize the controlled substance monitoring programs under the Public Health Service Act designed to foster the establishment of state-administered prescription drug monitoring programs (S 2529/HR 3528).
Keep the Promise to Seniors Act of 2014
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S557/HR1024 legislation that would expand Medicare Part D Medication Therapy Management benefit to one or more chronic diseases as defined in the legislation; Controlled substances -- advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled subances in the Medicare Part D program; Preferred networks - advocating that CMS recognize the importance of the useof preferred networks to improve pharmacy performance measures; CMS Proposed Rule/Medicare Part D, including HR 4160
Ensuring Seniors Access to Local Pharmacies Act of 2014
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Opposition to legislation that would amend Medicare Part D to require health plans to include any willing pharmacy in its network if the pharmacy is located in a medically underserved area or among a medically underserved population - HR 4577. Opposition to limiting the ability of health plans to include preferred networks in their pharmacy network.
Ensuring Seniors Access to Local Pharmacies Act of 2014
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Opposition to legislation that would amend Medicare Part D to require health plans to include any willing pharmacy in its network if the pharmacy is located in a medically underserved area of among a medically underserved population - H.R. 4577. Opposition to limiting the ability of health plans to include preferred networks in their pharmacy network.
National All Schedules Prescription Electronic Reporting Reauthorization Act of 2014
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Support for legislation (National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013- NASPER) to reauthorize the controlled substance monitoring programs under the Public Health Service Act designed to foster the establishment of state-administered prescription drug monitoring programs (S 2529/HR 3528).
National All Schedules Prescription Electronic Reporting Reauthorization Act of 2014
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Support for legislation (National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013 - NAPSER) to reauthorize the controlled substance monitoring programs under the Public Health Service Act designed to foster the establishment of state-administered prescription drug monitoring programs (S 2529/HR 3528).
National All Schedules Prescription Electronic Reporting Reauthorization Act of 2014
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Support for legislation (National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013-NASPER) to reauthorize the controlled substance monitoring programs under the Public Health Service Act designed to foster the establishment of state-administered prescription drug monitoring programs (S 2529/HR 3528)
Medication Therapy Management Empowerment Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S557/HR1024 legislation that would expand Medicare Part D Medication Therapy Management benefit to one or more chronic diseases as defined in the legislation; Controlled substances--advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program.
Medication Therapy Management Empowerment Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S557/HR 1024 legislation that would expand Medicare Part D Medication Therapy Management benefit to one or more chronic diseases as defined in the legislation; Controlled substances--advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program.
Medication Therapy Management Empowerment Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S557/HR1024 legislation that would expand Medicare Part D Medication Therapy Management benefit to one or more chronic diseases as defined in the legislation; Controlled substances -- advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled subances in the Medicare Part D program; Preferred networks - advocating that CMS recognize the importance of the useof preferred networks to improve pharmacy performance measures; CMS Proposed Rule/Medicare Part D, including HR 4160
Medication Therapy Management Empowerment Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S557/HR 1024 - legislation would expand Medicare Part D Medication Therapy Management benefit to one or more chronic disease as defined in the legislation; Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S77, S117/HR 1102 - legislation would require HHS Secretary to negotiate prescription drugprices on behalf of Medicare Part D plan sponsors; Controlled substances - advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program; Preferred networks - advocating that CMS recognize the importance of the use of preferred networks to improve pharmacy performance measures; Medicare Accountable Care Organizations (ACO) - supporting the inclusion on pharmacists as providers in ACOs as an amendment to the Medicare sustainable growth rate
Medication Therapy Management Empowerment Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors -- Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D -- S 557/HR 1024 -- legislation would expand Medication Therapy Management benefit to one or morechronic diseases as defined in the legislation
Medicare Prescription Drug Price Negotiation Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require the Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors - Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D.
Medicare Prescription Drug Price Negotiation Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S557/HR 1024 - legislation would expand Medicare Part D Medication Therapy Management benefit to one or more chronic disease as defined in the legislation; Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S77, S117/HR 1102 - legislation would require HHS Secretary to negotiate prescription drugprices on behalf of Medicare Part D plan sponsors; Controlled substances - advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program; Preferred networks - advocating that CMS recognize the importance of the use of preferred networks to improve pharmacy performance measures; Medicare Accountable Care Organizations (ACO) - supporting the inclusion on pharmacists as providers in ACOs as an amendment to the Medicare sustainable growth rate
Medicare Prescription Drug Price Negotiation Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors -- Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D -- S 557/HR 1024 -- legislation would expand Medication Therapy Management benefit to one or morechronic diseases as defined in the legislation
Medicare Drug Savings Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S557/HR 1024 - legislation would expand Medicare Part D Medication Therapy Management benefit to one or more chronic disease as defined in the legislation; Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S77, S117/HR 1102 - legislation would require HHS Secretary to negotiate prescription drugprices on behalf of Medicare Part D plan sponsors; Controlled substances - advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program; Preferred networks - advocating that CMS recognize the importance of the use of preferred networks to improve pharmacy performance measures; Medicare Accountable Care Organizations (ACO) - supporting the inclusion on pharmacists as providers in ACOs as an amendment to the Medicare sustainable growth rate
Medicare Drug Savings Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors -- Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D -- S 557/HR 1024 -- legislation would expand Medication Therapy Management benefit to one or morechronic diseases as defined in the legislation
Medicare Drug Savings Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require the Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors - Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D.
Safeguarding America's Pharmaceuticals Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs -- HR 2186 requires registration of manufacturers that compound and requires Secretary to develop list of drugs that cannot be compounded, generally does not apply to a licensed pharmacist compounding in a state licensed pharmacy -- S 957 legislation establishes uniform national policy for the drug supply chain -- HR 1919 legislation provides enhanced securityin the drug distribution chain
Safeguarding America's Pharmaceuticals Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs; HR 2186 requires registration of manufacturers that compound and requires Secretary to develop a list of drugs that cannot be compounded; S 957/HR 1919 legislation that establishes uniform national policy to protect the safety of the drug supply chain; biosimilar naming - supporting Congressional action to seek FDA decision on biosimilar naming
Safeguarding America's Pharmaceuticals Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs HR 2186 - requires registration of manufacturers that compound and requires Secretary to develop a list of drugs that cannot be compounded, generally does not apply to a licensed pharmacist compounding in a state licensed pharmacy. S 957 legislation establishes a uniform national policy for the drug supply chain HR 1919 legislation provides enhanced securityin the drug distribution chain
VALID Compounding Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs HR 2186 - requires registration of manufacturers that compound and requires Secretary to develop a list of drugs that cannot be compounded, generally does not apply to a licensed pharmacist compounding in a state licensed pharmacy. S 957 legislation establishes a uniform national policy for the drug supply chain HR 1919 legislation provides enhanced securityin the drug distribution chain
VALID Compounding Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs -- HR 2186 requires registration of manufacturers that compound and requires Secretary to develop list of drugs that cannot be compounded, generally does not apply to a licensed pharmacist compounding in a state licensed pharmacy -- S 957 legislation establishes uniform national policy for the drug supply chain -- HR 1919 legislation provides enhanced securityin the drug distribution chain
VALID Compounding Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs; HR 2186 requires registration of manufacturers that compound and requires Secretary to develop a list of drugs that cannot be compounded; S 957/HR 1919 legislation that establishes uniform national policy to protect the safety of the drug supply chain; biosimilar naming - supporting Congressional action to seek FDA decision on biosimilar naming
Medicare Prescription Drug Price Negotiation Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S557/HR 1024 - legislation would expand Medicare Part D Medication Therapy Management benefit to one or more chronic disease as defined in the legislation; Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S77, S117/HR 1102 - legislation would require HHS Secretary to negotiate prescription drugprices on behalf of Medicare Part D plan sponsors; Controlled substances - advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program; Preferred networks - advocating that CMS recognize the importance of the use of preferred networks to improve pharmacy performance measures; Medicare Accountable Care Organizations (ACO) - supporting the inclusion on pharmacists as providers in ACOs as an amendment to the Medicare sustainable growth rate
ObamaCare Repeal Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors -- Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D -- S 557/HR 1024 -- legislation would expand Medication Therapy Management benefit to one or morechronic diseases as defined in the legislation
ObamaCare Repeal Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require the Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors - Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D.
Medication Therapy Management Empowerment Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S557/HR 1024 - legislation would expand Medicare Part D Medication Therapy Management benefit to one or more chronic disease as defined in the legislation; Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S77, S117/HR 1102 - legislation would require HHS Secretary to negotiate prescription drugprices on behalf of Medicare Part D plan sponsors; Controlled substances - advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program; Preferred networks - advocating that CMS recognize the importance of the use of preferred networks to improve pharmacy performance measures; Medicare Accountable Care Organizations (ACO) - supporting the inclusion on pharmacists as providers in ACOs as an amendment to the Medicare sustainable growth rate
Medication Therapy Management Empowerment Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors -- Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D -- S 557/HR 1024 -- legislation would expand Medication Therapy Management benefit to one or morechronic diseases as defined in the legislation
Medicare Drug Savings Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S557/HR 1024 - legislation would expand Medicare Part D Medication Therapy Management benefit to one or more chronic disease as defined in the legislation; Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S77, S117/HR 1102 - legislation would require HHS Secretary to negotiate prescription drugprices on behalf of Medicare Part D plan sponsors; Controlled substances - advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program; Preferred networks - advocating that CMS recognize the importance of the use of preferred networks to improve pharmacy performance measures; Medicare Accountable Care Organizations (ACO) - supporting the inclusion on pharmacists as providers in ACOs as an amendment to the Medicare sustainable growth rate
Medicare Drug Savings Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors -- Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D -- S 557/HR 1024 -- legislation would expand Medication Therapy Management benefit to one or morechronic diseases as defined in the legislation
Medicare Drug Savings Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require the Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors - Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D.
Prescription Drug and Health Improvement Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require the Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors - Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D.
Prescription Drug and Health Improvement Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S557/HR 1024 - legislation would expand Medicare Part D Medication Therapy Management benefit to one or more chronic disease as defined in the legislation; Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S77, S117/HR 1102 - legislation would require HHS Secretary to negotiate prescription drugprices on behalf of Medicare Part D plan sponsors; Controlled substances - advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program; Preferred networks - advocating that CMS recognize the importance of the use of preferred networks to improve pharmacy performance measures; Medicare Accountable Care Organizations (ACO) - supporting the inclusion on pharmacists as providers in ACOs as an amendment to the Medicare sustainable growth rate
Prescription Drug and Health Improvement Act of 2013
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors -- Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D -- S 557/HR 1024 -- legislation would expand Medication Therapy Management benefit to one or morechronic diseases as defined in the legislation
Drug Supply Chain Security Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs -- HR 2186 requires registration of manufacturers that compound and requires Secretary to develop list of drugs that cannot be compounded, generally does not apply to a licensed pharmacist compounding in a state licensed pharmacy -- S 957 legislation establishes uniform national policy for the drug supply chain -- HR 1919 legislation provides enhanced securityin the drug distribution chain
Drug Supply Chain Security Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs HR 2186 - requires registration of manufacturers that compound and requires Secretary to develop a list of drugs that cannot be compounded, generally does not apply to a licensed pharmacist compounding in a state licensed pharmacy. S 957 legislation establishes a uniform national policy for the drug supply chain HR 1919 legislation provides enhanced securityin the drug distribution chain
Drug Supply Chain Security Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs; HR 2186 requires registration of manufacturers that compound and requires Secretary to develop a list of drugs that cannot be compounded; S 957/HR 1919 legislation that establishes uniform national policy to protect the safety of the drug supply chain; biosimilar naming - supporting Congressional action to seek FDA decision on biosimilar naming
Pharmaceutical Quality, Security, and Accountability Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs; HR 2186 requires registration of manufacturers that compound and requires Secretary to develop a list of drugs that cannot be compounded; S 957/HR 1919 legislation that establishes uniform national policy to protect the safety of the drug supply chain; biosimilar naming - supporting Congressional action to seek FDA decision on biosimilar naming
Pharmaceutical Quality, Security, and Accountability Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs -- HR 2186 requires registration of manufacturers that compound and requires Secretary to develop list of drugs that cannot be compounded, generally does not apply to a licensed pharmacist compounding in a state licensed pharmacy -- S 957 legislation establishes uniform national policy for the drug supply chain -- HR 1919 legislation provides enhanced securityin the drug distribution chain
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2018 · third_quarter · 3A
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Met with HHS officials regarding the Administration Blueprint to Lower Drug Prices. Submitted comments to HHS in response to Blueprint. Communications and correspondence related to suspension of claims under Medicare Part D for a credible allegation of fraud, electronic prescribing, and prior authorization under Medicare Part D contained in HR 6--The Opioid Crisis Response Act of 2018.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2018 · third_quarter · Q3
Met with HHS officials regarding the Administration Blueprint to Lower Drug Prices. Submitted comments to HHS in response to Blueprint. Communications and correspondence related to suspension of claims under Medicare Part D for a credible allegation of fraud, electronic prescribing, and prior authorization under Medicare Part D contained in HR 6--The Opioid Crisis Response Act of 2018.
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2018 · second_quarter · 2A
Submitted letter to the House Energy and Commerce Committee for the record in support of H.R. 4841 concerning standardizing electronic prior authorization for Medicare. Also sent a letter to Rep. Schweikert in support of H.R. 4841. Also sent a letter of support for H.R. 3528 for the House Energy and Commerce Committee record. H.R. 3528 provides for the e-prescribing of prescription drugs for controlled substances under Medicare Part D program. Participated in discussions on the need to address fraud, waste and abuse in the Medicare Part D program.
Submitted a letter to House Energy and Commerce Committee Chair and Ranking Member in support of H.R. 3545 - Overdose Prevention and Patient Safety Act. Also sent a letter for the House Energy and Commerce Committee record in support of H.R. 4275 which directs the Secretary of HHS to develop and disseminate materials, giving pharmacists the understanding and ability to decline to fill controlled substances prescriptions that are fraudulent, forged or appear to be for abuse or diversion. Sent a letter in support of S. 974, the CREATES Act to the Chairman and Ranking Member of the Senate Judiciary Committee. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2018 · second_quarter · Q2
Submitted a letter to House Energy and Commerce Committee Chair and Ranking Member in support of H.R. 3545 - Overdose Prevention and Patient Safety Act. Also sent a letter for the House Energy and Commerce Committee record in support of H.R. 4275 which directs the Secretary of HHS to develop and disseminate materials, giving pharmacists the understanding and ability to decline to fill controlled substances prescriptions that are fraudulent, forged or appear to be for abuse or diversion. Sent a letter in support of S. 974, the CREATES Act to the Chairman and Ranking Member of the Senate Judiciary Committee.
Submitted letter to the House Energy and Commerce Committee for the record in support of H.R. 4841 concerning standardizing electronic prior authorization for Medicare. Also sent a letter to Rep. Schweikert in support of H.R. 4841. Also sent a letter of support for H.R. 3528 for the House Energy and Commerce Committee record. H.R. 3528 provides for the e-prescribing of prescription drugs for controlled substances under Medicare Part D program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2018 · first_quarter · Q1
Submitted comments to CMS on Medicare Advantage and Medicare Part D Rule, joined other stakeholders in letter HHS OIG in support of a safe harbor provision for that would encourage development of value-based contracts for the Medicare and Medicaid populations,submitted comments to CMS on the 2019 draft Call letter and submitted letter to Rep. Schweikert in support of H.R. 4148 concerning standardizing electronic prior authorization for Medicare beneficiaries.
Joined other stakeholders in a letter to Reps. Mullin and Blumenauer of support for H.R. 3545 - Overdose Prevention and Patient Safety Act, also sent a letter of support of H.R. 3545 to House Energy and Commerce Committee in support of H.R.3545 , Joined other stakeholders in letter to Senate and House leadership in support of the CREATES Act (H.R.2212 and S. 974) Delivered remarks at FDA Opioid Policy Steering Committee on ways to address the opioid epidemic, dissemination of pharmacoeconomic information,submitted letter to House Energy and Commerce Committee in support of H.R. 2026 Pharmaceutical Information Exchange Act and submitted a letter to AHRQ in response to a request for information regarding patient reported outcomes measures.
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2017 · fourth_quarter · Q4
Submitted comments to CMMI on recommendations to transform Medicare and Medicaid Programs
Joint letter with other pharmacy associations submitted for the record in the House Energy and Commerce committee hearing on opioids in support of pharmacists being eligible for DATA waivers to provide Medication Assisted Therapy, Comments submitted to HHS Notice of Benefit and payment parameters for 2019;Comments submitted to FDA on direct to consumer advertising, Comments submitted to FDA on potential areas of focus for the opioid policy steering committee, comments submitted to the FTC on solutions and strategies to improve generic competition in the marketplace, comments submitted in response to a request for information from the House of Representatives Diabetes Caucus for information on value based contracting, dissemination of pharmaeconomic information, and H.R. 2026 Pharmaceutical Information Exchange Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS)
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2017 · third_quarter · Q3
Submitted comments to CMS on the CY 2018 updates to the Quality Payment Program. Submitted comments to CMS on the Draft CY 2018 Medicare Part B Physician Fee Schedule.
Letter submitted to the Honorable Kevin Brady as part of the National Quality Forum (NQF) coalition in support of continued funding for the NQF as part of the funding for Medicare. Participated in a lobby days program as a member of the Alliance for a Stronger FDA and met with Senate members of appropriations committee to request adequate funding for the FDA.
Letters of support for the CREATES Act (H.R. 2212 and S. 974), (H.R. 3545) The Overdose Prevention and Patient Safety Act and the Pharmaceutical Information Exchange Act(H.R. 2026). Comments to FDA on Hatch-Waxman reform to advocate for prohibition of strategies that unnecessarily delay the entry of generic drugs into the marketplace.
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2017 · second_quarter · Q2
Comments submitted advocating for transformation and modernization of the Medicare Part D program.
Letters of support for the CREATES Act (H.R. 2212 and S. 974), the FAST Act (H.R. 2051) and the Pharmaceutical Information Exchange Act(H.R. 2026). Comments to FDA on biosimilars and interchangeability,
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2017 · first_quarter · Q1
Urging SAMHSA and Congress to take steps to modernize the underlying statute for 42 C.F.R. Part 2 by making it consistent with HIPAA - currently substance abuse records are not allowed to be shared without specific consent
MTM comprehensive medication review standardization and testing and implementing and adopting SNOMED CT codes for MTM and comments on the 2018 Draft Medicare Call letter
Supporting the dissemination of pharmacoeconomic information and urging Congress to continue its efforts against allowing substandard and dangerous counterfeit drugs to be imported across U.S. borders
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2016 · fourth_quarter · Q4
Medicare Part D issues concerning managed care pharmacy, comments to FDA on BsUFA II reauthorization citing a need for biosimilars education and post market surveillance, comments in support of 21st Century Cures Act to support Section 3037 - Health care economic information, comments to CMS regarding implementation of CARA - P.L. 114-198, and comments to CMS on Medicare Part D MTM program. Meetings with Congressional office staff to seek support for amending current law consistent with HIPAA to allow health plans to access patient addiction records. Meeting with OMB to discuss impact of the SAMSHA pending final rule on confidentiality of substance abuse records (42 CFR Part 2).
21st century cures,Biosimilar naming, Medicare Part D, AMCP draft legislation - "Medicare Prescription Drug Anti-Fraud Act", Medicare Part B reimbursement of biosimilars, Medicare Part B Drug Demonstration Projects, Senate Innovations Initiative and Medication Therapy Management (MTM)
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2016 · third_quarter · Q3
Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, providing comments to the FDA on the impact of Risk Evaluation Mitigation Strategies (REMS), supporting H.R. 2841 designed to increase access to generic drugs and providing comments to CMS on benefit and payment parameters for 2017. Support S. 524 (CARA). Comments provided to SAMSHA and AHRQ on opioid abuse. Comments provided on S. 2700 concerning an exemption for biological medicines from USP standards for quality. Comments provided to CMS on MACRA proposed rule. Comments to FDA on biosimilars labeling draft guidance advocating for changes to the biosimilarity statement and biosimilar product identification and naming sections. Comments to the FDA on PDUFA VI reauthorization. for its continued focus on patient safety and quality patient care. Meetings with Congressional office staff to seek support for amending current law consistent with HIPAA to allow health plans to access patient addiction records.
Support for increased FDA funding
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2016 · second_quarter · Q2
Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, providing comments to the FDA on the impact of Risk Evaluation Mitigation Strategies (REMS), supporting H.R. 2841 designed to increase access to generic drugs and providing comments to CMS on benefit and payment parameters for 2017. Support S. 524 (CARA). Comments provided to SAMSHA and AHRQ on opioid abuse. Comments provided on S. 2700 concerning an exemption for biological medicines from USP standards for quality. Comments provided to CMS on MACRA proposed rule.
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries (S. 1913),Biosimilar naming, Medicare Part D, AMCP draft legislation - "Medicare Prescription Drug Anti-Fraud Act", Medicare Part B reimbursement of biosimilars, Medicare Part B Drug Demonstration Projects, Senate Innovations Initiative and Medication Therapy Management (MTM)
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2016 · first_quarter · Q1
Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, providing comments to the FDA on the impact of Risk Evaluation Mitigation Strategies (REMS), supporting H.R. 2841 designed to increase access to generic drugs and providing comments to CMS on benefit and payment parameters for 2017.
Support for increased FDA funding
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries (S. 1913),Biosimilar naming, Medicare Part D, AMCP draft legislation - "Medicare Prescription Drug Anti-Fraud Act", Medicare Part B reimbursement of biosimilars, Senate Innovations Initiative and Medication Therapy Management (MTM)
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2015 · fourth_quarter · Q4
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries (S. 1913),Biosimilar naming, Medicare Part D, AMCP draft legislation - "Medicare Prescription Drug Anti-Fraud Act", Medicare Part B reimbursement of biosimilars, Senate Innovations Initiative and Medication Therapy Management (MTM)
Support for increased FDA funding
Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, providing comments to the FDA on the impact of Risk Evaluation Mitigation Strategies (REMS), supporting H.R. 2841 designed to increase access to generic drugs and providing comments to CMS on benefit and payment parameters for 2017.
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2015 · third_quarter · Q3
Support for increased FDA funding
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries (S. 1913),Biosimilar naming, Medicare Part D, AMCP draft legislation - "Medicare Prescription Drug Anti-Fraud Act", Medicare Part B reimbursement of biosimilars, Senate Innovations Initiative
Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, supporting the reauthorization of the National All Schedules Prescription Electronic Reporting Act (S 480/HR 1725)and providing comments to CDC on opioid dispensing guidelines
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2015 · second_quarter · Q2
Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy
Support for increased FDA funding
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries,Biosimilar naming, Medicare Part D
Filing targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2015 · first_quarter · Q1
Support for increased FDA funding
21st century cures, Medicare Part D lock in programs, Biosimilar naming, Medicare Part D
Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy
Filing targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2014 · fourth_quarter · Q4
Opposition to legislation that would amend Medicare Part D to require health plans to include any willing pharmacy in its network if the pharmacy is located in a medically underserved area or among a medically underserved population - HR 4577. Opposition to limiting the ability of health plans to include preferred networks in their pharmacy network.
Support for legislation (National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013-NASPER) to reauthorize the controlled substance monitoring programs under the Public Health Service Act designed to foster the establishment of state-administered prescription drug monitoring programs (S 2529/HR 3528)
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2014 · third_quarter · 3A
Opposition to legislation that would amend Medicare Part D to require health plans to include any willing pharmacy in its network if the pharmacy is located in a medically underserved area of among a medically underserved population - H.R. 4577. Opposition to limiting the ability of health plans to include preferred networks in their pharmacy network.
Support for increased FDA funding.
Biosimilar naming - supporting Congressional action to seek FDA decision on biosimiar naming and supporting FTC study of effect of naming on competition.
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2014 · second_quarter · Q2
Support for increased FDA funding.
Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S557/HR 1024 legislation that would expand Medicare Part D Medication Therapy Management benefit to one or more chronic diseases as defined in the legislation; Controlled substances--advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program.
Support for legislation (National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013- NASPER) to reauthorize the controlled substance monitoring programs under the Public Health Service Act designed to foster the establishment of state-administered prescription drug monitoring programs (S 2529/HR 3528).
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2014 · second_quarter · Q2
Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S557/HR1024 legislation that would expand Medicare Part D Medication Therapy Management benefit to one or more chronic diseases as defined in the legislation; Controlled substances--advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program.
Support for increased FDA funding.
Support for legislation (National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013 - NAPSER) to reauthorize the controlled substance monitoring programs under the Public Health Service Act designed to foster the establishment of state-administered prescription drug monitoring programs (S 2529/HR 3528).
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2014 · first_quarter · Q1
Support for increased FDA funding
Biosimilar naming--supporting Congressional action to seek FDA decision on biosimilar naming
Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S557/HR1024 legislation that would expand Medicare Part D Medication Therapy Management benefit to one or more chronic diseases as defined in the legislation; Controlled substances -- advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled subances in the Medicare Part D program; Preferred networks - advocating that CMS recognize the importance of the useof preferred networks to improve pharmacy performance measures; CMS Proposed Rule/Medicare Part D, including HR 4160
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2013 · fourth_quarter · Q4
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S557/HR 1024 - legislation would expand Medicare Part D Medication Therapy Management benefit to one or more chronic disease as defined in the legislation; Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S77, S117/HR 1102 - legislation would require HHS Secretary to negotiate prescription drugprices on behalf of Medicare Part D plan sponsors; Controlled substances - advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program; Preferred networks - advocating that CMS recognize the importance of the use of preferred networks to improve pharmacy performance measures; Medicare Accountable Care Organizations (ACO) - supporting the inclusion on pharmacists as providers in ACOs as an amendment to the Medicare sustainable growth rate
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2013 · third_quarter · Q3
S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs -- HR 2186 requires registration of manufacturers that compound and requires Secretary to develop list of drugs that cannot be compounded, generally does not apply to a licensed pharmacist compounding in a state licensed pharmacy -- S 957 legislation establishes uniform national policy for the drug supply chain -- HR 1919 legislation provides enhanced securityin the drug distribution chain
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors -- Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D -- S 557/HR 1024 -- legislation would expand Medication Therapy Management benefit to one or morechronic diseases as defined in the legislation
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2013 · second_quarter · Q2
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require the Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors - Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D.
S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs HR 2186 - requires registration of manufacturers that compound and requires Secretary to develop a list of drugs that cannot be compounded, generally does not apply to a licensed pharmacist compounding in a state licensed pharmacy. S 957 legislation establishes a uniform national policy for the drug supply chain HR 1919 legislation provides enhanced securityin the drug distribution chain
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Support for increased FDA funding
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries (S. 1913),Biosimilar naming, Medicare Part D, AMCP draft legislation - "Medicare Prescription Drug Anti-Fraud Act", Medicare Part B reimbursement of biosimilars, Medicare Part B Drug Demonstration Projects, Senate Innovations Initiative and Medication Therapy Management (MTM)
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Support for increased FDA funding
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Support for increased FDA funding.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs; HR 2186 requires registration of manufacturers that compound and requires Secretary to develop a list of drugs that cannot be compounded; S 957/HR 1919 legislation that establishes uniform national policy to protect the safety of the drug supply chain; biosimilar naming - supporting Congressional action to seek FDA decision on biosimilar naming
Support for increased FDA funding
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE